Clavaseptin Palatable tablets anibiotic for cats and dogs-Hyperdrug

Presentation Three tablet strengths are available: Clavaseptin 50mg Palatable Tablets containing 40mg Amoxicillin (as trihydrate) and 10mg Clavulanic Acid (as potassium salt). For use in cats and dogs. Clavaseptin 250mg Palatable Tablets containing 200mg Amoxicillin (as trihydrate) and 50mg Clavulanic Acid (as potassium salt). For use in dogs. Clavaseptin 500mg Palatable Tablets containing 400mg Amoxicillin (as trihydrate) and 100mg Clavulanic Acid (as potassium salt). For use in dogs. Excipient: Brown Iron Oxide (E172) Uses in dogs: treatment or adjunctive treatment of periodontal infections caused by bacteria susceptible to amoxicillin in combination with clavulanic acid i.e. Pasteurella spp, Streptococcus spp and Escherichia coli. In cats: treatment of skin infections (including wounds and abscesses) caused by bacteria susceptible to amoxicillin in combination with clavulanic acid i.e. Pasteurella spp, Staphylococcus spp, Streptococcus spp and Escherichia coli.

Contra-indications, warnings, etc Do not use in case of hypersensitivity to penicillins or other substances of the β-lactam group. Do not administer to gerbils, guinea pigs, hamsters, rabbits and chinchillas. Caution is advised in the use of Clavaseptin in any other small pet (non food-producing) herbivores. Use of the product should be based on susceptibility testing. Vomiting and diarrhoea may be observed. Treatment may be continued depending on the severity of the undesirable effect observed and a benefit/risk evaluation by the veterinary surgeon. Hypersensitivity reactions (allergiv skin reactions, anaphylaxis) may be observed. In these cases, administration should be discontinued and a symptomatic treatment given. In animals with impaired liver and kidney function, the use of the product should be subject to a risk/benefit evaluation by the veterinary surgeon and the posology evaluated carefully. The safety of the product has not been established during pregnancy and lactation. Laboratory studies in rats have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. Use the product only accordingly to the benefit/risk assessment by the responsible veterinarian. The bactericidal activity of amoxicillin may be reduced by the simultaneous use of bacteriostatic substances such as macrolides, tetracyclines, sulfonamides and chloramphenicol. At three times the recommended dose for a period of 28 days, diarrhoea was observed in dogs. In the event of an overdose, symptomatic treatment is advised. Operator warning Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious. 1. Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations. 2. Handle this product with great care to avoid exposure, such as skin rash, you should seek medical advice and show the doctor this warning. 3. If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms and require urgent medical attention. Wash hands after handling the tablets Pharmaceutical precautions Do not store above 25°C. Store in the original package. Any unused product or waste material should be disposed of in accordance with national requirements.

Legal category POM-V (previously POM). Packaging Quantities Clavaseptin 50mg Palatable Tablets: 10 and 50 blisters of 10 tablets Clavaseptin 250mg Palatable Tablets: 10 and 25 blisters of 10 tablets Clavaseptin 500mg Palatable Tablets: 10 blisters of 10 tablets. Further information After oral administration at the recommended dose in dogs and cats, the absorption of amoxicillin and clavulanic acid is fast. In dogs, the maximum plasma concentration of amoxicillin of 8.5 µg/ml is reached in 1.4 h and the maximum plasma concentration of clavulanic acid of 0.9 µg/ml is reached in 0.9h. In cats, the maximum plasma concentration of amoxicillin of 6.6 µg/ml is reached in 1.8 h and the maximum plasma concentration of clavulanic acid of 3.7 µg/ml is reached in 0.75h. Elimination is also fast. After repeated oral administration of the recommended dose in dogs and cats, there is no accumulation of amoxicillin or clavulanic acid and the steady state is reached rapidly after first administration. Marketing authorisation number Clavaseptin 50mg Palatable Tablets: Vm 08007/4113. Clavaseptin 250mg Palatable Tablets: Vm 08007/4114. Clavaseptin 500mg Palatable Tablets: Vm 08007/4115.